The Drug-Induced Respiratory Disease Website and App

Trastuzumab emtansine (Ado-trastuzumab emtansine - TDM-1)

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.a

Pneumonitis (interstitial lung disease/ILD)

Publications

U?rakl? M, Araz M, Demirk?ran A, Çelik AF, Karakurt Ery?lmaz M, Karaa?aç M, Artaç M

Pneumonitis associated with Trastuzumab emtansine in a patient with metastatic breast cancer.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2021 Dec 22;;10781552211066073 — 2021 Dec 22 — 10781552211066073

Alkan A

Interstitial pneumonitis associated with trastuzumab emtansine.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2018 Nov 14;;1078155218813716 — 2018 Nov 14 — 1078155218813716

Egloff H, Kidwell KM, Schott A

Ado-Trastuzumab Emtansine-Induced Pulmonary Toxicity: A Single-Institution Retrospective Review.

Case reports in oncology 2018 May-Aug;11;527-533 — 2018 May-Aug — 527-533